Indian equity benchmarks declined for a third consecutive session on Tuesday, pressured by persistent foreign outflows, a record-weak rupee, and profit-booking after recent record highs.

The Nifty 50 fell 0.55% to close at 26,032.20, and the Sensex dropped 0.59% to 85,138.27. This follows a rally last week where both indices hit 14-month peaks, supported by strong corporate earnings, stable economic growth, and supportive government and central bank policies.

Market Breadth Weakens
The selling was broad-based, with fifteen of the sixteen major sectoral indices closing lower. The broader market also softened, with the small-cap index down 0.6% and the mid-cap index falling 0.2%.

Key Factors Pressuring Markets:

1. Foreign Outflows & Currency Weakness: Foreign portfolio investors (FPIs) have been net sellers for three straight sessions. This sustained selling pressure contributed to the Indian rupee hitting a fresh all-time low of 90 against the U.S. dollar in interbank trading after market hours.
2. Awaiting Catalysts: "We expect the market to remain range-bound due to a lack of major triggers in the near term, while the wait for the India-U.S. trade deal continues to get longer," said Dharmesh Kant, head of equity research at Cholamandalam Securities.
3. RBI Policy in Focus: Investors are also cautious ahead of the Reserve Bank of India's (RBI) monetary policy decision on Friday, with many expecting rates to be held steady given robust economic growth.

Sectoral & Stock-Specific Action:

• Financials Drag: The heavyweight financials sector was the biggest drag, falling 0.9%. HDFC Bank and ICICI Bank each fell 1.2%, weighed down by an index rebalancing announcement. The National Stock Exchange (NSE) has capped the weightage of the top three lenders in the Nifty Bank index, which will reduce the passive fund allocation to these stocks.
• Notable Movers:
  • Bajaj Housing Finance tumbled over 7% after its parent, Bajaj Finance, announced it would sell up to a 2% stake in the company via block deals at a discount.
  • Sun Pharma Advanced Research (SPARC) surged 20% after a U.S. court ruled in its favor regarding a Priority Review Voucher for its neonatal seizure treatment drug, Sezaby.

Looking Ahead:
Market direction is likely to hinge on the RBI's policy stance on Friday and any progress on the long-awaited India-U.S. trade deal.

*(Exchange Rate: $1 = ₹89.7675)*